These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12378365)

  • 1. A systematic review of health state utility values for osteoporosis-related conditions.
    Brazier JE; Green C; Kanis JA;
    Osteoporos Int; 2002 Oct; 13(10):768-76. PubMed ID: 12378365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An updated systematic review of Health State Utility Values for osteoporosis related conditions.
    Peasgood T; Herrmann K; Kanis JA; Brazier JE
    Osteoporos Int; 2009 Jun; 20(6):853-68. PubMed ID: 19271098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.
    Burge R; Dawson-Hughes B; Solomon DH; Wong JB; King A; Tosteson A
    J Bone Miner Res; 2007 Mar; 22(3):465-75. PubMed ID: 17144789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility values associated with osteoporotic fracture: a systematic review of the literature.
    Hiligsmann M; Ethgen O; Richy F; Reginster JY
    Calcif Tissue Int; 2008 Apr; 82(4):288-92. PubMed ID: 18404243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis.
    Hiligsmann M; Ethgen O; Bruyère O; Richy F; Gathon HJ; Reginster JY
    Value Health; 2009; 12(5):687-96. PubMed ID: 19508659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden.
    Ström O; Borgstrom F; Zethraeus N; Johnell O; Lidgren L; Ponzer S; Svensson O; Abdon P; Ornstein E; Ceder L; Thorngren KG; Sernbo I; Jonsson B
    Acta Orthop; 2008 Apr; 79(2):269-80. PubMed ID: 18484255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
    Jansen JP; Gaugris S; Bergman G; Sen SS
    Curr Med Res Opin; 2008 Mar; 24(3):671-84. PubMed ID: 18221588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Social and economic impact of osteoporosis. A review of the literature.
    Schütte HE
    Eur J Radiol; 1995 Sep; 20(3):165-9. PubMed ID: 8536741
    [No Abstract]   [Full Text] [Related]  

  • 9. The societal burden of osteoporosis in Sweden.
    Borgström F; Sobocki P; Ström O; Jönsson B
    Bone; 2007 Jun; 40(6):1602-9. PubMed ID: 17433804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model.
    Zethraeus N; Borgström F; Ström O; Kanis JA; Jönsson B
    Osteoporos Int; 2007 Jan; 18(1):9-23. PubMed ID: 17093892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in patients with osteoporosis.
    Lips P; van Schoor NM
    Osteoporos Int; 2005 May; 16(5):447-55. PubMed ID: 15609073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden of osteoporosis-related fractures in Medicaid.
    Rousculp MD; Long SR; Wang S; Schoenfeld MJ; Meadows ES
    Value Health; 2007; 10(2):144-52. PubMed ID: 17391423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and economic burden of osteoporosis in Switzerland.
    Svedbom A; Ivergård M; Hernlund E; Rizzoli R; Kanis JA
    Arch Osteoporos; 2014; 9():187. PubMed ID: 24970672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.
    Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
    Bone; 2008 Feb; 42(2):294-306. PubMed ID: 18053789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature.
    Fleurence RL; Iglesias CP; Torgerson DJ
    Osteoporos Int; 2006 Jan; 17(1):29-40. PubMed ID: 15981019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of fracture prevention in established osteoporosis.
    Jönsson B; Christiansen C; Johnell O; Hedbrandt J
    Osteoporos Int; 1995 Mar; 5(2):136-42. PubMed ID: 7599450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures.
    Orsini LS; Rousculp MD; Long SR; Wang S
    Osteoporos Int; 2005 Apr; 16(4):359-71. PubMed ID: 15340799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial.
    Majumdar SR; Johnson JA; Lier DA; Russell AS; Hanley DA; Blitz S; Steiner IP; Maksymowych WP; Morrish DW; Holroyd BR; Rowe BH
    Osteoporos Int; 2007 Mar; 18(3):261-70. PubMed ID: 17086470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.